|
1
|
Omuro A and DeAngelis LM: Glioblastoma and
other malignant gliomas: A clinical review. JAMA. 310:1842–1850.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ohgaki H and Kleihues P: Epidemiology and
etiology of gliomas. Acta Neuropathol. 109:93–108. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ostrom QT, Gittleman H, Liao P,
Vecchione-Koval T, Wolinsky Y, Kruchko C and Barnholtz-Sloan JS:
CBTRUS Statistical Report: Primary brain and other central nervous
system tumors diagnosed in the United States in 2010–2014.
Neuro-oncol. 19 Suppl 5:v1–v88. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
Classification of Tumors of the Central Nervous System: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gravendeel LA, Kouwenhoven MC, Gevaert O,
de Rooi JJ, Stubbs AP, Duijm JE, Daemen A, Bleeker FE, Bralten LB,
Kloosterhof NK, et al: Intrinsic gene expression profiles of
gliomas are a better predictor of survival than histology. Cancer
Res. 69:9065–9072. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Buckner J, Giannini C, Eckel-Passow J,
Lachance D, Parney I, Laack N and Jenkins R: Management of diffuse
low-grade gliomas in adults - use of molecular diagnostics. Nat Rev
Neurol. 13:340–351. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhao S, Cai J, Li J, Bao G, Li D, Li Y,
Zhai X, Jiang C and Fan L: Bioinformatic Profiling Identifies a
Glucose-Related Risk Signature for the Malignancy of Glioma and the
Survival of Patients. Mol Neurobiol. 54:8203–8210. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tomczak K, Czerwińska P and Wiznerowicz M:
The Cancer Genome Atlas (TCGA): An immeasurable source of
knowledge. Contemp Oncol (Pozn). 19(1A): A68–A77. 2015.PubMed/NCBI
|
|
9
|
Barretina J, Caponigro G, Stransky N,
Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV,
Sonkin D, et al: The Cancer Cell Line Encyclopedia enables
predictive modelling of anticancer drug sensitivity. Nature.
483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Consortium EP: ENCODE Project Consortium:
An integrated encyclopedia of DNA elements in the human genome.
Nature. 489:57–74. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Arita H, Yamasaki K, Matsushita Y,
Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M,
Shimizu S, et al: A combination of TERT promoter mutation and MGMT
methylation status predicts clinically relevant subgroups of newly
diagnosed glioblastomas. Acta Neuropathol Commun. 4:792016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brat DJ, Verhaak RG, Aldape KD, Yung WK,
Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O,
et al: Cancer Genome Atlas Research Network: Comprehensive,
Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl
J Med. 372:2481–2498. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Verhaak RG, Hoadley KA, Purdom E, Wang V,
Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al:
Cancer Genome Atlas Research Network: Integrated genomic analysis
identifies clinically relevant subtypes of glioblastoma
characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Cancer Cell. 17:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Diamandis P and Aldape KD: Insights From
Molecular Profiling of Adult Glioma. J Clin Oncol. 35:2386–2393.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang P, Cai J, Yan W, Zhang W, Wang Y,
Chen B, Li G, Li S, Wu C, Yao K, et al: CGGA project:
Classification based on mutations of TERT promoter and IDH
characterizes subtypes in grade II/III gliomas. Neuro-oncol.
18:1099–1108. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang P, Cai J, Yan W, Zhang W, Wang Y,
Chen B, Li G, Li S, Wu, Yao K, et al: CGGA project: Classification
based on mutations of TERT promoter and IDH characterizes subtypes
in grade II/III gliomas. Neuro-oncol. 18:1099–1108. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang L, Jiang T, Yuan F, Li GL, Cui Y,
Liu EZ and Wang ZC: Correlation of chromosomes 1p and 19q status
and expressions of O6-methylguanine DNA methyltransferase (MGMT),
p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO)
grades II and III: A clinicopathological study. Neuropathol Appl
Neurobiol. 35:367–379. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eckel-Passow JE, Lachance DH, Molinaro AM,
Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML,
Smirnov IV, et al: Glioma Groups Based on 1p/19q, IDH, and TERT
Promoter Mutations in Tumors. N Engl J Med. 372:2499–2508. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda
C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL,
Giovanella BC, et al: TERT promoter mutations occur frequently in
gliomas and a subset of tumors derived from cells with low rates of
self-renewal. Proc Natl Acad Sci USA. 110:6021–6026. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pekmezci M, Rice T, Molinaro AM, Walsh KM,
Decker PA, Hansen H, Sicotte H, Kollmeyer TM, McCoy LS, Sarkar G,
et al: Adult infiltrating gliomas with WHO 2016 integrated
diagnosis: Additional prognostic roles of ATRX and TERT. Acta
Neuropathol. 133:1001–1016. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang SI, Puc J, Li J, Bruce JN, Cairns P,
Sidransky D and Parsons R: Somatic mutations of PTEN in
glioblastoma multiforme. Cancer Res. 57:4183–4186. 1997.PubMed/NCBI
|
|
22
|
Koschmann C, Calinescu AA, Nunez FJ,
Mackay A, Fazal-Salom J, Thomas D, Mendez F, Kamran N, Dzaman M,
Mulpuri L, et al: ATRX loss promotes tumor growth and impairs
nonhomologous end joining DNA repair in glioma. Sci Transl Med.
8:328ra282016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dahiya S, Emnett RJ, Haydon DH, Leonard
JR, Phillips JJ, Perry A and Gutmann DH: BRAF-V600E mutation in
pediatric and adult glioblastoma. Neuro-oncol. 16:318–319. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wick W, Weller M, van den Bent M, Sanson
M, Weiler M, von Deimling A, Plass C, Hegi M, Platten M and
Reifenberger G: MGMT testing - the challenges for biomarker-based
glioma treatment. Nat Rev Neurol. 10:372–385. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Frattini V, Trifonov V, Chan JM, Castano
A, Lia M, Abate F, Keir ST, Ji AX, Zoppoli P, Niola F, et al: The
integrated landscape of driver genomic alterations in glioblastoma.
Nat Genet. 45:1141–1149. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
No authors listed. The future of cancer
genomics. Nat Med. 21:992015. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stratton MR, Campbell PJ and Futreal PA:
The cancer genome. Nature. 458:719–724. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Brennan CW, Verhaak RG, McKenna A, Campos
B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ,
Berman SH, et al: TCGA Research Network: The somatic genomic
landscape of glioblastoma. Cell. 155:462–477. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee JK, Wang J, Sa JK, Ladewig E, Lee HO,
Lee IH, Kang HJ, Rosenbloom DS, Camara PG, Liu Z, et al:
Spatiotemporal genomic architecture informs precision oncology in
glioblastoma. Nat Genet. 49:594–599. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cancer Genome Atlas Research Network:
Comprehensive genomic characterization defines human glioblastoma
genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yan W, Zhang W, You G, Zhang J, Han L, Bao
Z, Wang Y, Liu Y, Jiang C, Kang C, et al: Molecular classification
of gliomas based on whole genome gene expression: A systematic
report of 225 samples from the Chinese Glioma Cooperative Group.
Neuro-oncol. 14:1432–1440. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao Z, Meng F, Wang W, Wang Z, Zhang C
and Jiang T: Comprehensive RNA-seq transcriptomic profiling in the
malignant progression of gliomas. Sci Data. 4:1700242017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Madhavan S, Zenklusen JC, Kotliarov Y,
Sahni H, Fine HA and Buetow K: Rembrandt: Helping personalized
medicine become a reality through integrative translational
research. Mol Cancer Res. 7:157–167. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ballester LY, Fuller GN, Powell SZ, Sulman
EP, Patel KP, Luthra R and Routbort MJ: Retrospective Analysis of
Molecular and Immunohistochemical Characterization of 381 Primary
Brain Tumors. J Neuropathol Exp Neurol. 76:179–188. 2017.PubMed/NCBI
|
|
37
|
Ducray F, Marie Y and Sanson M: IDH1 and
IDH2 mutations in gliomas. N Engl J Med. 360:2248–2249; author
reply 2249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yan H, Parsons DW, Jin G, McLendon R,
Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ,
et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med.
360:765–773. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vijayakumar V, Liebisch G, Buer B, Xue L,
Gerlach N, Blau S, Schmitz J and Bucher M: Integrated multi-omics
analysis supports role of lysophosphatidylcholine and related
glycerophospholipids in the Lotus japonicus-Glomus intraradices
mycorrhizal symbiosis. Plant Cell Environ. 39:393–415. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Diplas BH, He X, Brosnan-Cashman JA, Liu
H, Chen LH, Wang Z, Moure CJ, Killela PJ, Loriaux DB, Lipp ES, et
al: The genomic landscape of TERT promoter wildtype-IDH wildtype
glioblastoma. Nat Commun. 9:20872018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Perry JR, Laperriere N, O'Callaghan CJ,
Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross
JG, Roa W, et al: Trial Investigators: Short-Course Radiation plus
Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med.
376:1027–1037. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Weller M, Stupp R, Reifenberger G, Brandes
AA, van den Bent MJ, Wick W and Hegi ME: MGMT promoter methylation
in malignant gliomas: Ready for personalized medicine? Nat Rev
Neurol. 6:39–51. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Petrova RS, Webb KF, Vaghefi E, Walker K,
Schey KL and Donaldson PJ: Dynamic functional contribution of the
water channel AQP5 to the water permeability of peripheral lens
fiber cells. Am J Physiol Cell Physiol. 314:C191–C201. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Binabaj MM, Bahrami A, ShahidSales S,
Joodi M, Mashhad Joudi M, Hassanian SM, Anvari K and Avan A: The
prognostic value of MGMT promoter methylation in glioblastoma: A
meta-analysis of clinical trials. J Cell Physiol. 233:378–386.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bao ZS, Chen HM, Yang MY, Zhang CB, Yu K,
Ye WL, Hu BQ, Yan W, Zhang W, Akers J, et al: RNA-seq of 272
gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in
secondary glioblastomas. Genome Res. 24:1765–1773. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Singh D, Chan JM, Zoppoli P, Niola F,
Sullivan R, Castano A, Liu EM, Reichel J, Porrati P, Pellegatta S,
et al: Transforming fusions of FGFR and TACC genes in human
glioblastoma. Science. 337:1231–1235. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Di Stefano AL, Fucci A, Frattini V,
Labussiere M, Mokhtari K, Zoppoli P, Marie Y, Bruno A, Boisselier
B, Giry M, et al: Detection, Characterization, and Inhibition of
FGFR-TACC Fusions in IDH Wild-type Glioma. Clin Cancer Res.
21:3307–3317. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lasorella A, Sanson M and Iavarone A:
FGFR-TACC gene fusions in human glioma. Neuro Oncol. 19:475–483.
2017.PubMed/NCBI
|
|
49
|
Li Y, Xu J, Chen H, Bai J, Li S, Zhao Z,
Shao T, Jiang T, Ren H, Kang C, et al: Comprehensive analysis of
the functional microRNA-mRNA regulatory network identifies miRNA
signatures associated with glioma malignant progression. Nucleic
Acids Res. 41:e2032013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Luo H, Chen Z, Wang S, Zhang R, Qiu W,
Zhao L, Peng C, Xu R, Chen W, Wang HW, et al: c-Myc-miR-29c-REV3L
signalling pathway drives the acquisition of temozolomide
resistance in glioblastoma. Brain. 138:3654–3672. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang Z, Zhang C, Liu X, Wang Z, Sun L, Li
G, Liang J, Hu H, Liu Y, Zhang W, et al: Molecular and clinical
characterization of PD-L1 expression at transcriptional level via
976 samples of brain glioma. OncoImmunology. 5:e11963102016.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang CB, Zhu P, Yang P, Cai JQ, Wang ZL,
Li QB, Bao ZS, Zhang W and Jiang T: Identification of high risk
anaplastic gliomas by a diagnostic and prognostic signature derived
from mRNA expression profiling. Oncotarget. 6:36643–36651.
2015.PubMed/NCBI
|
|
53
|
Lee Y, Scheck AC, Cloughesy TF, Lai A,
Dong J, Farooqi HK, Liau LM, Horvath S, Mischel PS and Nelson SF:
Gene expression analysis of glioblastomas identifies the major
molecular basis for the prognostic benefit of younger age. BMC Med
Genomics. 1:522008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Phillips HS, Kharbanda S, Chen R, Forrest
WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et
al: Molecular subclasses of high-grade glioma predict prognosis,
delineate a pattern of disease progression, and resemble stages in
neurogenesis. Cancer Cell. 9:157–173. 2006. View Article : Google Scholar : PubMed/NCBI
|
